Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Abbott Laboratories, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An examination of the long-term activity ratios reveals consistent, though generally declining, trends across the observed period from March 31, 2022, to December 31, 2025. The ratios indicate a gradual decrease in the efficiency with which assets and equity are being utilized to generate revenue.

Net Fixed Asset Turnover
The net fixed asset turnover ratio demonstrates a clear downward trajectory. Starting at 5.00 in March 2022, the ratio decreased to 3.75 by December 2025. While fluctuations exist within the period, the overall trend suggests diminishing efficiency in generating sales from fixed assets. The decline appears to accelerate slightly in the latter half of the observed timeframe.
Total Asset Turnover
The total asset turnover ratio exhibits a similar pattern of decline, though less pronounced than that of the net fixed asset turnover. Beginning at 0.60 in March 2022, the ratio decreased to 0.51 by December 2025. The ratio remained relatively stable between 0.55 and 0.56 for several quarters before the more noticeable decrease in later periods. This suggests a broader reduction in the efficiency of all assets in generating revenue.
Equity Turnover
The equity turnover ratio shows the most significant decline among the three ratios analyzed. Starting at 1.26 in March 2022, it decreased to 0.85 by December 2025. The rate of decline appears to increase after March 2024, indicating a weakening relationship between equity financing and revenue generation. This could suggest a less effective utilization of shareholder investment.

Collectively, these ratios suggest a consistent, albeit gradual, decrease in operational efficiency over the analyzed period. The declining trends warrant further investigation to determine the underlying causes, such as changes in sales strategies, asset management practices, or industry dynamics. The accelerating declines observed in the latter part of the period may indicate emerging challenges requiring attention.


Net Fixed Asset Turnover

Abbott Laboratories, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net sales
Net property and equipment
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net fixed asset turnover = (Net salesQ4 2025 + Net salesQ3 2025 + Net salesQ2 2025 + Net salesQ1 2025) ÷ Net property and equipment
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio demonstrates a clear declining trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio exhibited values above 5.00, but consistently decreased throughout the analyzed timeframe.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The ratio began at 5.00 in March 2022, showing a slight increase to 5.17 in June 2022 and 5.18 in September 2022. A subsequent decrease was observed in December 2022, falling to 4.76. This initial period suggests relatively efficient asset utilization, though a softening trend is apparent towards the end of the year.
Continued Decline (Mar 31, 2023 – Dec 31, 2024)
The downward trend accelerated in the following year. The ratio decreased from 4.47 in March 2023 to 3.95 by December 2024. This indicates a diminishing ability to generate sales revenue from the existing fixed asset base. Fluctuations within this period were minimal, suggesting a consistent, albeit negative, trajectory.
Latest Period (Mar 31, 2025 – Dec 31, 2025)
The decline continued, albeit at a slower pace, reaching 3.75 in December 2025. A slight increase to 3.81 was observed in September 2025, but this did not reverse the overall downward trend. The ratio stabilized in the 3.75-3.81 range during the last two quarters of the period.
Net Sales and Net Property, Plant, and Equipment Relationship
While net sales experienced fluctuations, they generally remained relatively stable over the period. However, net property and equipment consistently increased. This increase in fixed assets, coupled with relatively stable or slightly declining sales, is the primary driver of the observed decrease in the net fixed asset turnover ratio. The company is investing in more fixed assets, but not realizing a proportional increase in sales.

In summary, the net fixed asset turnover ratio indicates a decreasing efficiency in utilizing fixed assets to generate sales. This trend warrants further investigation to determine the underlying causes and potential implications for future profitability and investment strategies.


Total Asset Turnover

Abbott Laboratories, total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Total asset turnover = (Net salesQ4 2025 + Net salesQ3 2025 + Net salesQ2 2025 + Net salesQ1 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio exhibits a generally declining trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrate a relatively stable range, followed by a more pronounced decrease in later periods. This suggests a potential shift in the efficiency with which assets are being utilized to generate sales.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The ratio begins at 0.60 and fluctuates between 0.59 and 0.62 during this timeframe. This indicates a consistent, though modest, level of asset utilization. Net sales experienced a decline during this period, while total assets remained relatively stable, contributing to the observed ratio values.
Declining Trend (Mar 31, 2023 – Dec 31, 2024)
A clear downward trend emerges, with the ratio decreasing from 0.56 in March 2023 to 0.52 by December 2024. This decline coincides with a period of increasing total assets, while net sales remained relatively flat or experienced modest growth. The increase in assets without a proportional increase in sales is a primary driver of this decrease.
Recent Period (Mar 31, 2025 – Dec 31, 2025)
The ratio stabilizes at a lower level, fluctuating between 0.51 and 0.52. Total assets continue to increase significantly, reaching 86,713 US$ in millions by December 2025, while net sales show a slight increase. This suggests that the company is investing in assets at a faster rate than it is generating revenue, resulting in a continued lower asset turnover.
Overall Observation
The consistent decline in the total asset turnover ratio warrants further investigation. While a lower ratio does not necessarily indicate poor performance, it suggests the company may be overinvested in assets relative to its sales generation. Potential factors contributing to this trend could include strategic investments in long-term assets, inefficiencies in asset management, or a shift in business strategy. Further analysis, considering industry benchmarks and company-specific factors, is recommended.

Equity Turnover

Abbott Laboratories, equity turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net sales
Total Abbott shareholders’ investment
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Equity turnover = (Net salesQ4 2025 + Net salesQ3 2025 + Net salesQ2 2025 + Net salesQ1 2025) ÷ Total Abbott shareholders’ investment
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The equity turnover ratio demonstrates a clear declining trend over the observed period. Initially, the ratio fluctuated around 1.25-1.26 in the first four quarters of 2022, before beginning a consistent decrease.

Overall Trend
From a high of 1.26 in March 2022, the equity turnover ratio decreased to 0.85 by December 2025. This represents a substantial reduction in the efficiency with which shareholders’ investment is being utilized to generate sales.
Phase 1: Initial Stability (Mar 31, 2022 – Dec 31, 2022)
The ratio remained relatively stable, ranging between 1.19 and 1.26. This suggests a consistent level of sales generation relative to the shareholders’ investment during this period. Minor fluctuations were observed, but no significant directional movement was apparent.
Phase 2: Gradual Decline (Mar 31, 2023 – Dec 31, 2023)
A gradual downward trend commenced in the first quarter of 2023, with the ratio decreasing from 1.12 to 1.04. This indicates a slight decrease in the efficiency of equity utilization. The rate of decline was moderate during this phase.
Phase 3: Accelerated Decline (Mar 31, 2024 – Dec 31, 2025)
The rate of decline accelerated significantly from March 2024 onwards. The ratio fell from 1.04 to 0.85 over the final three quarters of the period. This suggests a more pronounced decrease in the effectiveness of shareholders’ investment in generating sales. The substantial increase in total shareholders’ investment, coupled with relatively stable net sales, likely contributed to this accelerated decline.

The consistent decrease in the equity turnover ratio warrants further investigation. While net sales remained relatively stable, the significant growth in total shareholders’ investment suggests that the company may be requiring more equity to generate the same level of sales. This could indicate diminishing returns on equity or a shift in capital allocation strategies.